Dermata Therapeutics Provides Corporate Update and Reports Full Year 2021 Financial Results

DMT310 Phase 2 rosacea trial is over two-thirds enrolled with topline results expected in H2 2022DMT310 Phase 2 psoriasis trial to start H1 2022, with topline results expected in H1 2023DMT310 Phase 3 moderate-to-severe acne trials planned for H1 …